SUPN - Supernus Pharmaceuticals, Inc.
| Previous Close | 35.06 |
| Open | 35.02 |
| Bid | 34.41 x 1000 |
| Ask | 37.65 x 900 |
| Day's Range | 33.46 - 36.20 |
| 52 Week Range | 30.05 - 61.25 |
| Volume | 950,815 |
| Avg. Volume | 578,330 |
| Market Cap | 1.887B |
| Beta (3Y Monthly) | 1.10 |
| PE Ratio (TTM) | 17.60 |
| EPS (TTM) | 2.05 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.75 |
- Simply Wall St.•2 days ago
A Note On Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) ROE and Debt To Equity
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. We'll use ROE to examine Supernus Pharmaceuticals...
- Markit•10 days ago
See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc NASDAQ NMS:SUPNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding SUPN are favorable, with net inflows of $2.49 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•18 days ago
Supernus' ADHD Candidate Positive in 4th Phase III Study
Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
- GlobeNewswire•18 days ago
Supernus Announces Webcast of Investor Day on April 16, 2019
ROCKVILLE, Md., April 01, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment.
- Simply Wall St.•18 days ago
Shareholders Are Thrilled That The Supernus Pharmaceuticals (NASDAQ:SUPN) Share Price Increased 296%
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shareholders might be concerned after seeing the share price drop 15% in...
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of SUPN earnings conference call or presentation 8-Aug-18 1:00pm GMT
Q2 2018 Supernus Pharmaceuticals Inc Earnings Call
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of SUPN earnings conference call or presentation 27-Feb-19 2:00pm GMT
Q4 2018 Supernus Pharmaceuticals Inc Earnings Call
- American City Business Journals•22 days ago
Supernus reports mixed ADHD drug trial results. So why isn't it worried?
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) reported Thursday mixed results from a phase 3 clinical trial for its attention deficit hyperactivity disorder treatment — and investors were not pleased. The Rockville company, which focuses on products for central nervous system diseases, failed to demonstrate that a 600-milligram dose of its drug candidate, called viloxazine hydrochloride, could effectively reduce ADHD symptoms in adolescents. The stock dipped Thursday as much as 4 percent to $32.90 per share before crawling up to $34.18, a 0.58 percent drop from Wednesday's closing price, by 3 p.m. But Supernus President and CEO Jack Khattar said this latest outcome won't stop the company from advancing the product to market, according to remarks he made on a conference call about the results.
- GlobeNewswire•23 days ago
Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced topline results from the second Phase III study of SPN-812 in adolescents (P304) for the treatment of attention deficit hyperactivity disorder (ADHD).
- GlobeNewswire•23 days ago
Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD
Supernus Pharmaceuticals, Inc. (SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Thursday, March 28, 2019, at approximately 8:00 a.m. ET, it will issue a press release announcing the results of its final Phase III study for SPN-812 in patients 12-17 years old (P304) for the treatment of attention deficit hyperactivity disorder (ADHD). The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy.
- Simply Wall St.•last month
What Investors Should Know About Supernus Pharmaceuticals, Inc.’s (NASDAQ:SUPN) Financial Strength
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), with a market cap of US$2.0b, are often out of theRead More...
- GlobeNewswire•last month
Recent Analysis Shows Golar LNG, AG Mortgage Investment Trust, AmerisourceBergen, Caesarstone, Dycom Industries, and Supernus Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•last month
Supernus to Present at the 2019 Cowen Health Care Conference
ROCKVILLE, Md., March 06, 2019 -- Supernus Pharmaceuticals, Inc. (NASADQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment.
- GuruFocus.com•2 months ago
Supernus Pharmaceuticals Inc (SUPN) Files 10-K for the Fiscal Year Ended on December 31, 2018
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Warning! GuruFocus has detected 5 Warning Sign with G. Click here to check it out.
- American City Business Journals•2 months ago
New Enterprise Associates is raising its biggest fund yet. Here's how much it's going for.
Chevy Chase venture capital juggernaut New Enterprise Associates Inc. is raising a new fund with a ceiling of $3.6 billion, according to a Securities and Exchange Commission filing made Friday. New Enterprise Associates 16, which the company raised in 2017, was $3.5 billion, according to PitchBook. NEA has increased its fund size each time since its first $16 million fund in 1978.
- MoneyShow•2 months ago
Supernus Pharmaceuticals- Migraines, Epilepsy and ADHD
Supernus Pharmaceuticals (SUPN) potentially offers a rare combination of traditional value, backed by sales of its approved drugs, and upside excitement thanks to its high-potential pipeline assets, asserts growth stock expert Doug Gerlach, editor of Investor Advisory Service.
Motley Fool•2 months agoSupernus Pharmaceuticals Inc (SUPN) Q4 2018 Earnings Conference Call Transcript
SUPN earnings call for the period ending December 31, 2018.
- ACCESSWIRE•2 months ago
Supernus Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2019 / Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 27, ...
- GlobeNewswire•2 months ago
Supernus Announces Record Full Year 2018 Financial Results
Fourth quarter 2018 total revenue of $115.9 million, a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million, a 32% increase over 2017.Fourth.
- Simply Wall St.•2 months ago
Should You Be Worried About Insider Transactions At Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...
- GlobeNewswire•2 months ago
Supernus to Host Fourth Quarter and Full Year 2018 Earnings Conference Call
ROCKVILLE, Md., Feb. 12, 2019 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Simply Wall St.•3 months ago
An Intrinsic Calculation For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shows It’s 45.76% Undervalued
Want to participate in a short research study? Help shape the future of investing tools and receive a $60 prize! I am going to run you through how I calculated Read More...
- Motley Fool•3 months ago
3 Top Small-Cap Stocks to Buy Right Now
Think software-as-a-service, neurology drugs, and marijuana.
